Home / Research Library / ARIAD Pharmaceuticals, Inc. Receives a Patent for Kinase Inhibitors
GIPResearch.com · Patent and Technology Research
ARIAD Pharmaceuticals, Inc. Receives a Patent for Kinase Inhibitors
ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development, and commercialization of medicines to transform the lives of cancer patients. The Company's approach to structure-based drug design has led to several molecularly targeted medicines for drug-resistant…
ARIAD Pharmaceuticals, Inc. Receives a Patent for Kinase Inhibitors — research background
Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.
ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development, and commercialization of medicines to transform the lives of cancer patients. The Company's approach to structure-based drug design has led to several molecularly targeted medicines for drug-resistant and difficult-to-treat cancers.
In India, the Pharmaceutical business of ARIAD Pharmaceuticals, Inc. is focused on Cell Proliferation in EGFR-Driven Cancer. Cell Proliferation in ALK-Driven Cancers, Synthesis of Multimerizing Agents, Acetylenic Heteroaryl Compounds.
ARIAD Pharmaceuticals, Inc. filed a patent application numbered 1963/KOLNP/2011 that is titled as PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS. This patent application has been granted as Patent Number 297333.The invention covers the field of chemical compounds. The invention relates to a compound of Formula or a Tautomer, a pharmaceutically acceptable salt, or a sovate thereof wherein the components represent an aryl membered carbocyclic. During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that the claims relate to mere new form of known substances already disclosed by the prior art documents. Further, the claimed compounds could not show any significant difference in property with regards to therapeutic efficacy. As a response to the said objection, the applicant responded by submitting technical and scientific arguments by submitting that the new compound formed is structurally (scientific structure) different.Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
Discuss a research question related to ARIAD Pharmaceuticals, Inc. Receives a Patent for
Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.
Source and context: Original GIPResearch.com publication dated 2019-08-08. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.